What is the use of heparin sodium injection?
Pharmaceutical Product Monograph: Heparin Sodium Injection (1,000 IU/mL to 25,000 IU/mL)
In the pharmaceutical industry, Heparin Sodium is a high-potency, parenteral Anticoagulant (glycosaminoglycan). As a pharmacist and manufacturer, I view this molecule as the “Immediate-Action Blood Thinner”—it is technically designed as a highly sulfated polysaccharide that provides instantaneous anticoagulation, making it the frontline defense in emergency cardiovascular and surgical medicine.
At your WHO-GMP facility in Mumbai, Heparin is a critical Life-Saving SKU. Unlike oral anticoagulants that take days to work, Heparin’s effect is immediate when given intravenously, which is why it is indispensable for hospital-based critical care.
Therapeutic Profile: Primary Indications
Heparin Sodium is indicated for the prevention and treatment of thromboembolic disorders.
| Indication | Clinical Context | Technical Rationale |
| Acute DVT / PE | Emergency Medicine | Gold Standard: Used to stop the growth of existing clots in the legs (DVT) or lungs (PE). |
| Myocardial Infarction | Acute Heart Attack | Prevents the extension of coronary artery clots during the acute phase of a heart attack. |
| Open Heart Surgery | Cardiovascular Surgery | Prevents blood from clotting while it is being circulated through a heart-lung bypass machine. |
| Hemodialysis | Renal Care | Injected into the dialysis circuit to prevent the blood from “crashing” or clotting in the artificial kidney. |
| Atrial Fibrillation | Stroke Prevention | Used for rapid anticoagulation in patients with AFib who are at high risk for systemic emboli. |
Mechanism: Antithrombin III Potentiation
Heparin does not “dissolve” clots; rather, it stops the body’s clotting engine:
Catalytic Binding: Heparin binds to a natural plasma protein called Antithrombin III (ATIII).
Structural Change: This binding causes a technical “conformational change” in ATIII, increasing its efficiency by nearly 1,000 times.
Enzyme Neutralization: The Heparin-ATIII complex then inactivates Thrombin (Factor IIa) and Activated Factor X (Xa).
Chain Termination: Without Thrombin, the conversion of Fibrinogen to Fibrin is blocked, effectively halting the formation of a stable blood clot.
The Pharmacist’s “Technical Warning”
The “HIT” Syndrome: As a pharmacist, I must emphasize the risk of Heparin-Induced Thrombocytopenia (HIT). This is a technical immune reaction where the body attacks its own platelets, paradoxically causing more clots. Platelet counts must be monitored every 2–3 days.
The Antidote: In cases of severe bleeding (overdose), the technical “reversal agent” is Protamine Sulfate. 1 mg of Protamine neutralizes approximately 100 units of Heparin.
Monitoring (aPTT): For standard Unfractionated Heparin (UFH), the activated Partial Thromboplastin Time (aPTT) must be measured frequently to ensure the dose is within the therapeutic window (usually 1.5 to 2.5 times the control).
No IM Use: Heparin should never be given via Intramuscular (IM) injection due to the extreme risk of massive hematomas (deep muscle bleeding).
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Biological Source” USP: Heparin is traditionally derived from Porcine (Pig) Intestinal Mucosa. On your digital marketplace, highlight your traceability and viral inactivation protocols. This is a critical technical requirement for registration in the EU and US markets.
The “Preservative-Free” vs. “MDV” Advantage: Market both Single-Dose Vials (Preservative-Free) for surgical use and Multi-Dose Vials (with Benzyl Alcohol) for dialysis units. Providing both options is a major B2B advantage in international hospital tenders.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Heparin 5,000 IU and 25,000 IU vials to support your registration in international B2B tenders for cardiology and renal care.